Atomwise vs Genesis Molecular AI (2026)
Search chemical space or invent new chemical space, which is the oldest split in computational chemistry. Atomwise screens ultra large synthesizable libraries with a deep convolutional network predicting bioactivity in three dimensions, and it published its own denominator, reporting how many selected compounds were tested and how many held up, which almost nobody in this category does. Genesis designs, integrating language models, diffusion and physics into a discovery platform from a research lineage. They are sequential rather than competing, and the question to put to both is identical and rarely answered: how many of your molecules were actually synthesised, and how many worked. A design or a hit that cannot be made is a delay, not a discovery.
- The method is in the peer reviewed literature, with the core screening result published and the network described rather than called proprietary.
- It reports its own denominator, publishing how many model selected compounds were tested and how many held up.
- Virtual screening against ultra large synthesizable libraries is a specific and measurable substitution for physical high throughput screening.
- The platform integrates language models, diffusion and physics into small molecule discovery from a research lineage rather than assembling tools around a services business.
- Generative design with a stated technical approach lets a medicinal chemistry team evaluate the method rather than a demonstration.
- For a partner wanting molecule design capability specifically, a focused discovery platform is a different purchase from a screening service.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Atomwise and Genesis Molecular AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Atomwise | Genesis Molecular AI |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | Not recorded | 2019 |
| Headquarters | San Francisco, CA | Burlingame, CA |
| Website | atomwise.com | genesis.ml |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Atomwise its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Genesis Molecular AI, Atomwise grades higher on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Genesis Molecular AI its top capability grade on AI Centrality. Set against Atomwise, Genesis Molecular AI does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Autonomy and Oversight Model and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Atomwise or Genesis Molecular AI?
The AI Health Index grades Atomwise higher than Genesis Molecular AI on every axis that separates them, several axes, including Model and Technology Transparency, Clinical and Operational Evidence and AI Governance and Bias Disclosure. Genesis Molecular AI does not grade higher on any scored axis.
Where do Atomwise and Genesis Molecular AI differ most?
The widest separation the AI Health Index records between Atomwise and Genesis Molecular AI is on Clinical and Operational Evidence, where Atomwise grades A and Genesis Molecular AI grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Atomwise and Genesis Molecular AI grade the same?
The AI Health Index grades Atomwise and Genesis Molecular AI the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
These are sequential steps rather than substitutes, since one searches existing chemical space for compounds likely to bind and the other proposes molecules that do not exist yet, and a programme may use both. The comparable to ask each for is what proportion of computationally selected or designed molecules were synthesised and tested and how many survived, because a proposal that cannot be made or does not hold up is a delay rather than a discovery. Neither holds a located security attestation and neither publishes pricing.